S2-E34 - #ILC2021 Day Three - Multi-Disciplinary NAFLD Thinking, with Exciting Drugs on the Horizon
Send us a text Manal Abdelmalek, Ian Rowe and first-timer Ken Cusi join Louise Campbell and Roger Green to review a thought-provoking, assumption-challenging Day Three of #ILC2021. Most of the presentations the panel covered focused on medications, the core ideas and discussions spoke to changes in thinking. One theme that ran through the discussion was about multi-disciplinary care...and not only because Fatty Liver Endocrinologist Ken Cusi was on the panel. Another was to think about drugs ...
25 Juni 20211h 13min
S2-E33 - #ILC2021 Day Two -- Learning About Patients Through Large Databases
Send us a text Jörn Schattenberg, Naim Alkhouri, Dr. Michelle Long of Boston University and Livia Alimena of the Global Liver Institute join Roger to review highlights of Day Two at ILC2021. Each panelist reviewed a favorite presentation of the day, most of which involved learning about the nature of disease through large population analysis. In the course of the discussion, the group discussed lean NASH, COVID-19, food insufficiency, AI and cohort analyses. What did these topics have in comm...
24 Juni 20211h 14min
S2-E32 - Leaders Provide Perspectives on #ILC2021
Send us a text Incoming EASL Secretary General Prof. Thomas Berg, Global Liver Institute President and CEO Donna Cryer and Genfit Head of Global Diagnostics Suneil Hosmane share their unique perspectives on Digital ILC 2021 with Roger Green. In our lead-in episode for #ILC2021, Roger Green conducts interviews with three leaders, each with a unique perspective on what they value about this week's Congress. Incoming EASL Secretary General Prof. Thomas Berg discusses his view on the various ways...
24 Juni 202158min
S2-E31.3 - Previewing Digital ILC 2021 -- Part II -- NITs, late-breakers and intriguing topics
Send us a text Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green identify specific sessions and presentations they believe will bring the greatest enlightenment around tough challenges and unaddressed issues in Fatty Liver disease. The topics the Surfers identify vary greatly, from cirrhosis to NITs to public policy issues such as the relationship between food insecurity and NAFLD prevalence. The range of these topics speaks to the breadth and vitality of Digital ILC 2021, ...
20 Juni 202112min
S2-E31.2 - Previewing Digital ILC 2021 -- Part II -- Drug Development
Send us a text Stephen Harrison and Jörn Schattenberg discuss what the titles of Digital ILC 2021 presentations tell us about possible findings in drug development. Drug development presentations will occur throughout Digital ILC 2021, ranging from late-breakers to general session presentations to dedicated sessions. Stephen and Jörn use the titles of presentation to discuss areas of drug development, paying particular attention to treating cirrhosis on one end and drugs that address de...
19 Juni 202112min
S2-E31.1 - Previewing Digital ILC 2021 -- Part II -- "Favorite Things" and Discussing Metabolic issues
Send us a text Jörn Schattenberg and the regular Surfers identify one thing about the Digital ILC 2021 meeting they anticipate eagerly and fall into a discussion about pharmacologic and non-pharmacologic approaches to managing metabolic issues. As the group looked forward to Digital ILC 2021, each panelist identified one source of particular excitement. The answers varied all the way from process (enough time for interaction between speakers) to session themes to individual pieces of content....
19 Juni 202114min
S2-E31 - DIgital ILC 2021 -- Preview II
Send us a text Joern Schattenberg joins the Surfers to identify exciting presentations and sessions from the Digital ILC 2021 meeting. Digital ILC 2021 kicks off one week from today, with four days of sessions covering the entire range of liver topics. Professor Schattenberg joins Dr. Stephen Harrison, Louise Campbell and Roger Green in identifying presentations, sessions and major themes they believe will import new knowledge and even change the ways we look at NAFLD and NASH. Wa...
17 Juni 202144min
S2-E30.3 - The Global Liver institute US NASH Action Plan - treatment and health system challenges
Send us a text Global Liver Institute Director of Global Policy Andrew Scott, Madrigal Pharmaceuticals Co-Founder and CMO Becky Taub, and Central Virginia VA Health Care System Chief of Hepatology and Gastroenterology Dr. Michael Fuchs discuss GLI's US NASH Action Plan and steps different stakeholders can take to support the Plan. In this conversation, the group considers systems issues ranging from commitment to multi-disciplinary approaches to including Fatty Liver metrics in metrics like H...
13 Juni 202116min
